“…KRM‐II‐81, one of the most recent GABAkines to be considered for clinical development (Cerne et al., 2021; Witkin et al, 2022), was rationally designed to overcome the metabolic liabilities of the predecessor imidazodiazepine GABAkine, HZ‐166. KRM‐II‐81 is an oxazole bioisostere of HZ‐166 with the oxazole replacing the metabolically‐vulnerable ester function of HZ‐166 (Poe et al., 2016).…”
Section: Discussionmentioning
confidence: 99%
“…The present experiments explored predicted metabolic sites on the KRM-II-81 molecule and provide a new orally active anticonvulsant agent (D5-KRM-II-81). imidazole [1,5α][1,4]diazepin-3-yl) oxazole) is a new GABAkine (gamma aminobutyric acid A [GABA A ] receptor potentiator) with anticonvulsant, anxiolytic, and antinociceptive activity in preclinical models (Biggerstaff et al, 2020;Cerne et al, 2019;Knutson et al, 2020;Lewter et al, 2017;Poe et al, 2016;Witkin et al, 2017Witkin et al, , 2018Witkin et al, , 2019Witkin et al, , 2020Witkin et al, , 2022. This imidazodiazepine, is one of several new GABAkines that have recently been targeted for clinical investigation (Cerne et al, 2021).…”
The imidazodiazepine, (5‐(8‐ethynyl‐6‐(pyridin‐2‐yl)‐4H‐benzo [f]imidazole[1,5‐α][1,4]diazepin‐3‐yl) oxazole or KRM‐II‐81) is a new α2/3‐selective GABAkine (gamma aminobutyric acid A receptor potentiator) with anticonvulsant, anxiolytic, and antinociceptive activity in preclinical models. Reducing metabolism was utilized as a means of potentially extending the half‐life of KRM‐II‐81. In vitro and in vivo studies were conducted to evaluate metabolic liabilities. Incubation of KRM‐II‐81 in hepatocytes revealed sites of potential metabolism on the oxazole and the diazepine rings. These sites were targeted in the design of a deuterated analog (D5‐KRM‐II‐81) that could be evaluated as a potentially longer‐acting analog. In contrast to computer predictions, peak plasma concentrations of D5‐KRM‐II‐81 in rats were not significantly greater than those produced by KRM‐II‐81 after oral administration. Furthermore, brain disposition of KRM‐II‐81 was higher than that of D5‐KRM‐II‐81. The half‐life of the two compounds in either plasma or brain did not statistically differ from one another but the tmax for D5‐KRM‐II‐81 occurred slightly earlier than for KRM‐II‐81. Non‐metabolic considerations might be relevant to the lack of increases in exposure by D5‐KRM‐II‐81. Alternative sites of metabolism on KRM‐II‐81, not targeted by the current deuteration process, are also possible. Despite its lack of augmented exposure, D5‐KRM‐II‐81, like KRM‐II‐81, significantly prevented seizures induced by pentylenetetrazol when given orally. The present findings introduce a new orally active anticonvulsant GABAkine, D5‐KRM‐II‐81.
“…KRM‐II‐81, one of the most recent GABAkines to be considered for clinical development (Cerne et al., 2021; Witkin et al, 2022), was rationally designed to overcome the metabolic liabilities of the predecessor imidazodiazepine GABAkine, HZ‐166. KRM‐II‐81 is an oxazole bioisostere of HZ‐166 with the oxazole replacing the metabolically‐vulnerable ester function of HZ‐166 (Poe et al., 2016).…”
Section: Discussionmentioning
confidence: 99%
“…The present experiments explored predicted metabolic sites on the KRM-II-81 molecule and provide a new orally active anticonvulsant agent (D5-KRM-II-81). imidazole [1,5α][1,4]diazepin-3-yl) oxazole) is a new GABAkine (gamma aminobutyric acid A [GABA A ] receptor potentiator) with anticonvulsant, anxiolytic, and antinociceptive activity in preclinical models (Biggerstaff et al, 2020;Cerne et al, 2019;Knutson et al, 2020;Lewter et al, 2017;Poe et al, 2016;Witkin et al, 2017Witkin et al, , 2018Witkin et al, , 2019Witkin et al, , 2020Witkin et al, , 2022. This imidazodiazepine, is one of several new GABAkines that have recently been targeted for clinical investigation (Cerne et al, 2021).…”
The imidazodiazepine, (5‐(8‐ethynyl‐6‐(pyridin‐2‐yl)‐4H‐benzo [f]imidazole[1,5‐α][1,4]diazepin‐3‐yl) oxazole or KRM‐II‐81) is a new α2/3‐selective GABAkine (gamma aminobutyric acid A receptor potentiator) with anticonvulsant, anxiolytic, and antinociceptive activity in preclinical models. Reducing metabolism was utilized as a means of potentially extending the half‐life of KRM‐II‐81. In vitro and in vivo studies were conducted to evaluate metabolic liabilities. Incubation of KRM‐II‐81 in hepatocytes revealed sites of potential metabolism on the oxazole and the diazepine rings. These sites were targeted in the design of a deuterated analog (D5‐KRM‐II‐81) that could be evaluated as a potentially longer‐acting analog. In contrast to computer predictions, peak plasma concentrations of D5‐KRM‐II‐81 in rats were not significantly greater than those produced by KRM‐II‐81 after oral administration. Furthermore, brain disposition of KRM‐II‐81 was higher than that of D5‐KRM‐II‐81. The half‐life of the two compounds in either plasma or brain did not statistically differ from one another but the tmax for D5‐KRM‐II‐81 occurred slightly earlier than for KRM‐II‐81. Non‐metabolic considerations might be relevant to the lack of increases in exposure by D5‐KRM‐II‐81. Alternative sites of metabolism on KRM‐II‐81, not targeted by the current deuteration process, are also possible. Despite its lack of augmented exposure, D5‐KRM‐II‐81, like KRM‐II‐81, significantly prevented seizures induced by pentylenetetrazol when given orally. The present findings introduce a new orally active anticonvulsant GABAkine, D5‐KRM‐II‐81.
“… 10 The efficacy of KRM-II-81 is associated with a low sedative and motor-impairing profile, lack of tolerance development, and abuse liability. 2 , 10 Further, KRM-II-81 is efficacious in models of pharmacoresistant epilepsy 7 and did not produce tolerance. 7 , 11 In animal models used to predict drug abuse liability, KRM-II-81 differentiated from classical GABAkines like midazolam or diazepam.…”
Section: Introductionmentioning
confidence: 93%
“…KRM-II-81 is the latest in a series of imidazodiazepine potentiators of GABA A receptors (GABAARs) or GABAkines that is under development. 1 , 2 KRM-II-81 produces anxiolytic effects, 3 , 4 antidepressant-like activity, 5 anticonvulsant activity, 6 − 9 and efficacy in a host of acute and chronic pain models in rodents. 10 The efficacy of KRM-II-81 is associated with a low sedative and motor-impairing profile, lack of tolerance development, and abuse liability.…”
Section: Introductionmentioning
confidence: 99%
“… 7 , 11 In animal models used to predict drug abuse liability, KRM-II-81 differentiated from classical GABAkines like midazolam or diazepam. 2 …”
Imidazodiazepine (5-(8-ethynyl-6-(pyridin-2-yl)-4
H
-benzo[
f
]imidazole[1,5-α][1,4]diazepin-3-yl)
oxazole or KRM-II-81) is a potentiator of GABA
A
receptors
(a GABAkine) undergoing preparation for clinical development. KRM-II-81
is active against many seizure and pain models in rodents, where it
exhibits improved pharmacological properties over standard-of-care
agents. Since salts can be utilized to create opportunities for increased
solubility, enhanced absorption, and distribution, as well as for
efficient methods of bulk synthesis, a hydrochloride salt of KRM-II-81
was prepared. KRM-II-81·HCl was produced from the free base with
anhydrous hydrochloric acid. The formation of the monohydrochloride
salt was confirmed by X-ray crystallography, as well as
1
H NMR and
13
C NMR analyses. High water solubility and
a lower partition coefficient (octanol/water) were exhibited by KRM-II-81·HCl
as compared to the free base. Oral administration of either KRM-II-81·HCl
or the free base resulted in high concentrations in the brain and
plasma of rats. Oral dosing in mice significantly increased the latency
to both clonic and tonic convulsions and decreased pentylenetetrazol-induced
lethality. The increased water solubility of the HCl salt enables
intravenous dosing and the potential for higher concentration formulations
compared with the free base without impacting anticonvulsant potency.
Thus, KRM-II-81·HCl adds an important new compound to facilitate
the development of these imidazodiazepines for clinical evaluation.
A series of imidazodiazepines has been developed that possess reduced sedative liabilities but retain efficacy in anticonvulsant screening models. The latest of these compounds, (5-(8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazole [1,5-α][1,4]diazepin-3-yl) oxazole known as KRM-II-81) is currently awaiting advancement into the clinic. A deuterated structural analog (D5-KRM-II-81) was
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.